• SRAX’s Sequire SaaS platform provides tools to help public companies track shareholders, manage warrants, issue shareholder surveys
• SRAX recently featured in Wall Street Journal article highlighting volatility problems for public companies
• Sequire subscriber base doubled between Q3 and Q4 2020 to 183 public companies across 5 million+ active traders, investors

SRAX (NASDAQ: SRAX), a financial technology company, helps publicly traded companies unlock data and insights with Sequire, its SaaS investor analytics platform that features a unique set of tools that allows users to track investors, manage warrants, publish news and issue surveys. Since its creation in 2019, the platform has bloomed to over 5 million active retail investors across 180+ companies (https://ibn.fm/6cBli), nearly doubling its year-over-year bookings to $10 million in the first quarter of 2021 (https://ibn.fm/HHR8w). “Retail investors are more important now than ever, as they have been driving the market, and companies are starting to pay attention,” said SRAX founder and CEO Christopher Miglino. “Data on who investors are and what they invest in is a valuable asset to every public company. This data provides us deep insights into trends and movements of all types of investors.” Economic and political factors underpinned the severe market volatility experienced throughout much of 2020 and early 2021. Miglino was recently featured in a Wall Street Journal article highlighting the crippling volatility issues faced by public companies and how SRAX can help them address the problem (https://ibn.fm/4psZ9). “Our sales have increased significantly over the past two quarters,” Miglino stated in the article, confirming that the platform provides critical information about shareholder activity. As a company that went public in 2012, SRAX management intimately understands the challenges faced by public companies, and built the platform specifically to help managers unlock the power of critical market data. Features like the Situation Room produce real-time market information, including level two trading data, current share price, volume change, % change, and more. In addition, the warrant management feature manages warrant holders’ activity and keeps track of warrant expiration dates while calculating proceeds at different price scenarios in an interactive data-driven environment. Sequire doesn’t stop at providing insights – the platform allows users to take action through communication1 tools that engage new and existing investors through marketing campaigns across email, social media, and more. “Our team did an amazing job in delivering a number of cutting-edge technological improvements to the platform and they have laid the foundation for some amazing enhancements that we will bring to market throughout the rest of this year,” said Miglino. “I could not be more proud of the hard work and dedication that the team has demonstrated as our sales continue to skyrocket.” SRAX is committed to helping public companies unlock the power of data through Sequire, its premier investor intelligence and communication SaaS platform. As concerns about market volatility continue to mount, public companies are turning to Sequire to access tools that provide clarity, increase engagement, and build loyalty with shareholders. For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Before global pandemic, telehealth was more of novelty than necessity
• Virtual care resonating with patients; almost 88% want to continue using telehealth after COVID-19 has passed
• Earlier this year, ISWH launched TeleCare Home Health LLC, a wholly owned telehealth and home healthcare subsidiary

Even as COVID-19 appears to be subsiding in the United States, the impact of the pandemic will likely have long-lasting impact in many industries. An area of great interest to ISW Holdings (OTC: ISWH), a global brand management holdings company, is telehealth because the company has commercial operations in that space. A recent Healthcare Finance articles reported that almost 88% of Americans want to continue using telehealth for nonurgent consultations even after COVID-19 has passed (https://ibn.fm/98pHO). “Before the COVID-19 pandemic, telehealth was more of a novelty than a necessity,”     the article stated. “The concept of touching base with a doctor remotely was promising, but there were hurdles. Now, though, with many of those hurdles at least temporarily lifted — due to policy changes at the federal level — more consumers have received a taste of what telehealth is like. And most liked it, at least enough to want to keep using it after the pandemic has become a memory. “That was the main finding of a new Sykes survey that polled 2,000 Americans in March on how their opinions on virtual care have changed within the past year,” the article continued. “And it comes at a time when most Americans have now experienced telehealth in some form: In March 2020, fewer than 20% had experienced a telehealth appointment. By March of this year, more than 61% had undergone a telehealth visit.” The article goes on to note that numbers recorded over that same year suggest virtual care is resonating with patients. “A year ago, about 65% of Americans felt hesitant or doubtful about the quality of telehealth, and 56% did not believe it was possible to receive the same level of care as compared to in-person appointments,” the article observed. “Now, almost 88% want to continue using telehealth for nonurgent consultations after COVID-19 has passed, while almost 80% say it’s possible to receive quality care.” The continuation of telehealth as an option in the medical care could be a boon to patients and healthcare providers alike. The survey reported some of the reasons patients preferred virtual visits. “A significant number, 61%, experienced telehealth for the first time because their physician’s office moved their appointments to virtual visits,” the article stated. “Twenty-eight percent said it was a convenient option for immediate care, while about 24% proactively asked their physicians office to switch to virtual appointments. About 18% made the switch after reading more about telehealth, 17% were persuaded by people they know, and 12% became convinced to try it after learning more about it from broadcast news.” While telehealth was a popular — and common option during the pandemic, not everyone has had a telehealth experience. However, a vast majority of those who haven’t yet tried telehealth, more than 77%, say they’re more willing to do so, as compared to 59% a year ago. “Meanwhile about 40% feel that the quality is comparable to an in-person visit, a 9% jump from 2020,” the survey continued. “Further data details the extent to which Americans are warming to telehealth. Eighty-five percent say it has made it easier to get the care they need; 62% said they were afraid of going to the doctor, but those fears were eased during their telehealth visit; 51% say they’re able to see their doctor more often; 31% say their healthcare costs have decreased; and 31% feel their doctor comes across as more empathetic during virtual visits. Finally, “three-quarters said they believe telehealth will become the norm for nonurgent medical consultations after the pandemic, and about 65% said they’d prefer to have parts of their annual physical done remotely,” the survey noted. All those numbers point to good things for ISWH, as projections for the virtual care during 2020 looks to reach at least $29 billion in total healthcare services; the same forecast notes that up to $106 billion of current U.S. healthcare spend could be virtualized by 2023. “This highlights the high rates of adoption among both patients and physicians, and the impetus felt among providers to offer safe, secure and easy-to-use virtual services as demand for telehealth continues to grow.” ISWH has already established itself as a technology, home healthcare and wellness company. Earlier this year, the company officially announced its launch of TeleCare Home Health LLC, a wholly owned telehealth and home healthcare subsidiary (https://ibn.fm/a35kk). For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• GTVH closes on acquisition of the Lodge Winery & Olive Oil Co. under the company’s Food & Wine Division, Napa Wine Brands Inc.
• Included in the acquisition is a wide range of brands and products.
• Company committed to broaden horizon of food and wine company by creating a platform different than anything seen in the northern hemisphere.

Golden Triangle Ventures (OTC: GTVH) is making a strong statement about its confidence in the $67-billion U.S. wine industry (https://ibn.fm/nvRRP) with its recent acquisition announcement. In May, the company acquired the Lodge Winery & Olive Oil Co. under the company’s Food & Wine Division, Napa Wine Brands Inc. (https://ibn.fm/dJZ1c). “Our marketing team is now ready to launch an in-depth program focused on driving our products into big box stores, smaller retail outlets, online platforms and many other avenues,” said Golden Triangle Ventures CEO Steffan Dalsgaard. “We have great relations with many people in the food and beverage industry, and we also intend to develop many brands and products within Napa Wine Brands that will supply some of our future endeavors across other divisions within Golden Triangle Ventures. We are working directly with Arron and his team to grow their bulk inventory and launch all of these products for the world to enjoy.” Napa Wine Brands was founded by CEO Arron Johnson, a longtime resident of the famed northern California Sonoma and Napa Valley wine country regions. Included in the newly announced acquisition is a wide range of brands and products under the Napa Wine Brands, Inc. umbrella, which now includes the Lodge Winery & Olive Oil Co. The Lodge Winery & Olive Oil Co. is an established wine brand that produces award-winning wines and locally grown and milled single-varietal extra virgin olive oils along with a variety of award-winning wine vinegars. Currently, the winery offers wines from Napa Valley and Sonoma County as well as surrounding regions. Napa Wine Brands is committed to manufacture and distribute specialty wines, foods and unique wine country gift items as well as explore an array of other potential markets in the gift, food and beverage industry. The company is committed to broaden the horizon of a traditional food and wine company by creating a platform different than anything currently seen in the northern hemisphere. “I’m beyond excited about this acquisition and what the future has in store for Napa Wine Brands and the many other upcoming brands and products I’ve developed that are associated with the Lodge Winery & Olive Oil Co.,” said Johnson. “We intend to develop this company into a premium destination winery in the number-one attraction of California, the wine country.” Golden Triangle Ventures is a multifaceted consulting company with many projects being developed that provide synergistic values in the health, entertainment and technology industries. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities. Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. For more information, visit the company’s website at www.GoldenTriangleInc.com. NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• BAND Royalty has rolled out its first of four series of visionary NFT collectibles, granting them unique status by attaching them to potential revenue opportunities stemming from music artist royalties
• BAND’s stable of music royalty possibilities includes songs sung by artists such as Beyonce, Cher, Justin Timberlake, and Rihanna in its first series
• BAND’s art DeFi offering helps fans claim a personal financial stake in beloved music artists
• The remaining three series of NFT offerings, each with 3,000 “albums” of graduated levels of rarity, with roll out of over the next 18 months along with an NFT-supported token that provides fans further opportunities to share in music royalties
• The first series of NFTs launched with a private pre-sale that netted BAND more than $700,000 in Ethereum equivalence before transferring the remainder of the albums to the public market

The non-fungible token (“NFT”) market gained a revolutionary new player this year when BAND Royalty applied its experience in music industry investments to the digital art collectibles arena in order to create a new type of best-of-both-worlds product. “I’ve been buying and investing in (music royalties) for almost 20 years,” BAND co-founder Noble Drakoln said during a live-streamed raffle of the final number in BAND’s first series of NFT “albums” May 27 (https://ibn.fm/mKrDa). “As I’ve been in the NFT space helping other companies, I realized that there was an opportunity to merge both NFT art, which was getting really popular, … with a potential DeFi project that allowed people to share in music royalties. Because, why not? Most art and most NFTs have nothing behind them. It’s just what (investors) think other people think is going to be more valuable.” BAND Royalty’s first series of 3,000 NFTs, available for sale to the public May 15 following a private pre-sale that alone netted over $700,000 in Ethereum equivalence from the most-sought-after albums in the series, presents digital works of art in a forum typical of NFT collectibles and then offers opportunities for the buyers to stake the NFTs if they want to use them to obtain a pooled apportionment of select musicians’ royalties. The first series includes royalties from music catalog selections featuring artists such as Justin Timberlake, Jay-Z, Beyonce and Timbaland. “It’s a secret hidden world of investing. People don’t know they can buy performance royalties of major acts. … And that these rights are always floating out there for people to acquire them on various songs that these artists performed on,” Drakoln said during the album raffle, which highlighted BAND’s collaboration with crypto exchange LATOKEN. “We listen to all these people on the radio and we don’t know that there’s actually an income stream being developed.” BAND’s website illustrates the process for obtaining potential earnings from the NFTs, beginning with a purchase of lowest vinyl-level albums (the series includes a scaled roster of increasing rarity of albums from vinyl through varied gold and platinum levels to the most-limited diamond levels) for 1 ETH each using a Metamask or Trust wallet. That puts the buyer in BAND’s Music Mogle Club, and qualifies the buyer for staking opportunities in pools that may derive royalties either from published printing of the songs, mechanical reproductions of the songs or synchronization of the songs in outside media such as ads or movies. Then, every time a song earns royalties in the applicable pooled category, 50 percent of the revenue is divvied up among the people holding shares in the pool. “These are amazing ways to participate and to really give extra value to the beauty of the NFT art you collect,” Drakoln said, noting that BAND will also tokenize the NFTs once the first series is completed to allow more people to participate and have an opportunity to access the music royalties. The company plans to have a maximum of 12,000 BAND NFTs divided among four different series, with the remaining three series to be released over the next 18 months (https://ibn.fm/00j9v). BAND also expects to eventually launch its own music label with a cadre of artists. “We’re one of the most unique NFTs in the marketplace. No one’s ever seen this. We’re attached to world-class platinum performers,” Drakoin said. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND

• SRAX’s Sequire SaaS platform provides tools to help public companies track shareholders, manage warrants, issue shareholder surveys
• SRAX recently featured in Wall Street Journal article highlighting volatility problems for public companies
• Sequire subscriber base doubled between Q3 and Q4 2020 to 183 public companies across 5 million+ active traders, investors

SRAX (NASDAQ: SRAX), a financial technology company, helps publicly traded companies unlock data and insights with Sequire, its SaaS investor analytics platform that features a unique set of tools that allows users to track investors, manage warrants, publish news and issue surveys. Since its creation in 2019, the platform has bloomed to over 5 million active retail investors across 180+ companies (https://ibn.fm/6cBli), nearly doubling its year-over-year bookings to $10 million in the first quarter of 2021 (https://ibn.fm/HHR8w). “Retail investors are more important now than ever, as they have been driving the market, and companies are starting to pay attention,” said SRAX founder and CEO Christopher Miglino. “Data on who investors are and what they invest in is a valuable asset to every public company. This data provides us deep insights into trends and movements of all types of investors.” Economic and political factors underpinned the severe market volatility experienced throughout much of 2020 and early 2021. Miglino was recently featured in a Wall Street Journal article highlighting the crippling volatility issues faced by public companies and how SRAX can help them address the problem (https://ibn.fm/4psZ9). “Our sales have increased significantly over the past two quarters,” Miglino stated in the article, confirming that the platform provides critical information about shareholder activity. As a company that went public in 2012, SRAX management intimately understands the challenges faced by public companies, and built the platform specifically to help managers unlock the power of critical market data. Features like the Situation Room produce real-time market information, including level two trading data, current share price, volume change, % change, and more. In addition, the warrant management feature manages warrant holders’ activity and keeps track of warrant expiration dates while calculating proceeds at different price scenarios in an interactive data-driven environment. Sequire doesn’t stop at providing insights – the platform allows users to take action through communication tools that engage new and existing investors through marketing campaigns across email, social media, and more. “Our team did an amazing job in delivering a number of cutting-edge technological improvements to the platform and they have laid the foundation for some amazing enhancements that we will bring to market throughout the rest of this year,” said Miglino. “I could not be more proud of the hard work and dedication that the team has demonstrated as our sales continue to skyrocket.” SRAX is committed to helping public companies unlock the power of data through Sequire, its premier investor intelligence and communication SaaS platform. As concerns about market volatility continue to mount, public companies are turning to Sequire to access tools that provide clarity, increase engagement, and build loyalty with shareholders. For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Friendable’s Fan Pass platform has provided revenue streams for artists that may not have existed due to the global pandemic
• Version 2.0 of the Fan Pass artist streaming platform to be released on July 24, 2021, which also marks the first anniversary of the platform
• Friendable has signed a Letter of Intent for the production of musical-artist NFTs and the creation of a “Fanpasscrypto” marketplace

The global music streaming market was valued at $24.4 billion in 2020 and is expected to grow by a CAGR of 17.8%, resulting in $76.9 billion in revenue by 2027 (https://ibn.fm/v0NFs). The increase is largely driven by the COVID-19 pandemic, with a growing number of users turning to streaming platforms in the absence of live events. Even with the lockdown restrictions from the COVID-19 pandemic loosening, many venues have not opened their doors to full capacity. Companies like Friendable (OTC: FDBL), and its immersive artist streaming platform Fan Pass, are helping the music industry overcome pandemic challenges by offering multiple revenue-generating opportunities for artists both online and in venues, in a new and exciting model to promote and enjoy music. Launched at the height of the pandemic, the Fan Pass live streaming platform was designed to help artists maintain and find new earning opportunities, as well as give fans access to the artists they love, and support the industry in general. The platform has since grown exponentially and has become a valuable tool for artists to continue sharing their work, generating fan engagement and revenue, even as venues are opening. To provide even more value to its artist members and fans, Friendable is launching a 2.0 version of the Fan Pass platform, with new features and benefits for users, while also running a comprehensive 120-day strategy designed to build value in the business of livestreaming and live event content. “These next several months are going to lead us to and eventually through our version 2 mobile and web app releases, which will include an entirely new suite of features, virtual currency options, automation and, ultimately, scale,” Friendable CEO Robert A. Rositano Jr. said (https://ibn.fm/08Rjh). “It is our intent to grow our base, build our revenues and begin monetizing across the board, which we believe to be very achievable based on the results we have seen since our launch and every month following. It’s time to unveil several new features to our artists, and we look forward to watching the artists’ revenues, along with the company’s steadily increase with this next version. Stay tuned!” The Fan Pass platform is a virtual stage where artists and fans unite for one-of-a-kind shows and interactions through mobile or desktop applications. Initially launched on July 24, 2020, Fan Pass didn’t start gaining momentum until the beginning of 2021, now doubling and tripling artist sign-ups. The 2.0 version of the application is coming out on July 24, 2021, exactly one year since the initial product was launched. Fans who want to subscribe to the live music streaming platform can do so online, with a monthly plan costing about what a music download would cost on another platform. Fans can also opt for a yearly plan – gaining access to a 20% discount on the plan overall. Additionally, users can sign up for the exclusive “All Access VIP” content, which includes:

• Live performances and online concerts
• Livestreaming studio sessions
• Backstage meetups – before, during, and after a set
• Behind-the-scenes footage of video and photoshoots
• Special interviews and one-on-one videos
• Streaming highlights from “a day in the life” of a fan’s favorite artist

Artists can sign up for the Fan Pass platform for free, gaining access to a dashboard of options that allow for uploading exclusive content right away. Each artist is eligible for various revenue streams through the engagement of fans and participation in live streaming events. For example, exclusive “ticket-only” performances gain artists 100% of the sales for their shows. Through Fan Pass, artists can also take advantage of the Pro Services, which offer artists merchandising, marketing, and other helpful tools (without the necessity of a record label). Recently, Friendable and Santo Blockchain Labs and Santo Mining Corp. (OTC: SANP) signed a Letter of Intent to further extend revenue opportunities to develop global entertainment and musical-artist driven non-fungible tokens (“NFTs”). NFTs are units of data stored on the blockchain, certifying that the asset is unique and not interchangeable. The agreement also calls for the creation of an exclusive “Fanpasscrypto” marketplace (https://ibn.fm/hhoZ6). The company also rewards top artists for engagement every month, running month-long contests with cash and tangible rewards. In the past, prizes have included cash, GoPros, merchandising packages, marketing packages, streaming gear, and more. The Fan Pass platform is poised to offer even more features and opportunities for artists and fans in the upcoming 2.0 release. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Infobird is launching the Next Generation of SaaS in China to grab a massive share of the massive and growing cloud infrastructure market
• The company is leveraging the huge growth opportunity represented by the boom of cloud infrastructure triggered by the shift towards cloud computing by businesses
• Inforbird is one of the few SaaS companies that can serve SMEs with its no-code development platform

Infobird (NASDAQ: IFBD) is a business-to-business (“B2B”) artificial intelligence (“AI”) solutions company, focused on developing AI-driven customer engagement solutions, especially for the finance segment. A premier provider of customer engagement software-as-a-service (“SaaS”) solutions in China, the company is leveraging automated and smart capabilities to maximize value for its clients. Infobird has a long-standing reputation for offering advanced cloud computing solutions to increase revenue, reduce costs, and enhance service quality and customer satisfaction. At present, Infobird is launching the next generation of SaaS in China to ride on the high growth wave in the cloud infrastructure sector. This mammoth growth can be predicted by China’s accelerating cloud migration attributed to the long-term digitalization trends of the country’s economy plus a surge in use of cloud and SaaS solutions by business enterprises. The emergence of the pandemic which led to remote work opportunities has also accelerated the increased acceptance of cloud business services (https://ibn.fm/UsDQW). Over 90% of companies in China are still small- to medium-sized enterprises (“SMEs”), which contribute roughly 60% to China’s GDP. SMEs have a lower revenue contribution although their customization needs are not very complex as compared to bigger enterprises. SaaS companies that can solve these complex issues and offer viable solutions will emerge victorious in grabbing a significant share of the market revenue. While SME‘s do not have the budget for significant hardware and software updates, they can switch to SaaS subscription for improved services and reduced costs. Inforbird is one of the few SaaS companies well-equipped to serve the SME’s by leveraging its no-code development platform. Moreover, China’s SaaS market is fragmented and the top 10 vendors make up only 35% of the total market share. This leaves an enormous potential in the SaaS market to be explored by an efficient newcomer. With its many years of operational experience in the country, Infobird has served many leading enterprises in various industries, such as China Guangfa Bank and multinational eCommerce giant Alibaba Group Holding Limited (NYSE: BABA). For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Lexaria announced significant strides in six of its studies within the 2021 applied R&D program
• All the studies are based on Lexaria’s DehydraTECH(TM) technology and are designed for multiple market applications, including oral nicotine, NSAIDs, antivirals, and hypertension
• The 2021 applied R&D program is intended to generate not only confirmatory results and data evidencing but also foster strategic commercial opportunities and corporate relationships

Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX) released a status report on six of its studies in the 2021 applied research and development (“R&D”) program. The program mainly involves studies using DehydraTECH(TM) 2.0 formulations, with different market areas of applications including oral nicotine, NSAIDs, antivirals, and hypertension. The announcement marks a significant milestone for Lexaria’s R&D program, and in an official statement announcing the status report, Lexaria also noted that the other ongoing studies would be reported separately (https://ibn.fm/OecRU). This comes after it announced a status report on two antiviral drug studies in the applied R&D program (https://ibn.fm/RVqds). The six programs covered in this announcement included:

• VIRAL-A20-2
• VIRAL-A20-3
• VIRAL-MC21-1-A
• HYPER-A21-1 and HYPER-A21-2
• NSAID-A21-1, and
• Oral Nicotine: NIC-C21-1 (Now NIC-A21-1)

VIRAL-A20-2 A tolerability and pharmacokinetic or (“PK”) study in animals using antiviral drugs. The program involved four groups of 10 animals, each dosed to determine if DehydraTECH-enhanced remdesivir and ebastine are well tolerated by the subjects and is evaluating peak concentration and total drug delivery into the bloodstream in comparison to non-enhanced controls, as is the case for other antiviral drugs. VIRAL-A20-3 An additional tolerability and PK study in animals evaluating Area Under the Curve for three other antiviral drugs.  Lexaria reported that all animal dosing and in-life procedures were completed, with sample analysis still ongoing, with a view to reporting soon. The study involved six groups of 10 animals. It is examining tolerability and quantity of drug delivery for three other antiviral drugs of interest that showed promise in their usage against the COVID-19 SARS-CoV-2 virus. Lexaria indicated that the study is projected to generate reportable results either in July or August. VIRAL-MC21-1 This study being performed by Canada’s National Research Council is exploring Nuclear Magnetic Resonance (“NMR”) and Liquid Chromatography-High Resolution Mass Spectrometry (“LC-HRMS”) and their application on 5 DehydraTECH-enhanced antiviral drug formulations already being studied under VIRAL-A20-2 and VIRAL-A20-3. VIRAL-MC21-1 recognizes how important molecular characterization is as a step towards determining whether the DehydraTECH technology alters the underlying drugs significantly enough to yield covalently-bonded new molecular entities (“NMEs”). These NMEs are usually subjected to stringent regulatory examination and approval processes than their non-NME alternatives. In previous studies, Lexaria has reported that NME formation did not occur following DehydraTECH formulation with other substances of interest, mainly cannabidiol (“CBD”) and nicotine. The results from this project are expected to be reported ahead of schedule. The company is targeting the announcement for the first half of July. Hyper-A21-1 and Hyper-A21-2 This study followed blood pressure testing in animals, building on previously reported successful PK study findings. It demonstrated statistically significant gains in CBD absorption relative to controls using Lexaria’s latest DehydraTECH 2.0 formulation innovations, according to results released back on May 6 (https://ibn.fm/kGrFL) and 20, 2021 (https://ibn.fm/hQ2f6). The study still requires some work, and the testing laboratory responsible for the initial research has been engaged for these follow-up tests. They will involve monitoring real-time animal blood pressure in response to specific formulations from the PK evaluations. Lexaria hopes that the work will complement previous human clinical study findings that showed a reduction in blood pressure following the use of DehydraTECH-CBD. Animal dosing and in-life procedures are yet to commence but will be reported as soon as there are significant developments in the study. NSAID-A21-1 This research is exploring the tolerability and PK study in animals, with a focus on ibuprofen and naproxen. Test articles were manufactured back in April, as scheduled, with subsequent contracts executed in early May involving animal testing laboratory performing the work. The initial animal dosing started on the week of May 17, ahead of schedule. The project is currently underway with a focus on pilot tolerability evaluations in rodents. The goal is to determine dosing that shows superior gastrointestinal tolerability, pitting Lexaria’s DehydraTECH test articles against concentration-matched controls. Pending a successful outcome of the pilot tolerability investigation, formal pharmacokinetic testing will follow.  Updates will be provided as soon as there are significant developments in the study. Oral Nicotine: NIC-C21-1 (now NIC-A21-1) This is a tolerability and PK study among animals evaluating oral nicotine. It was renamed following the move from an in vitro cell based study to an in vivo study in live anesthetized animals. This move allows Lexaria to conduct a superior evaluation of the systemic absorption of nicotine upon oral pouch product dosing within animals. Lexaria recognizes that human oral pouch dosing is a growing trend in various locations around the world. This redesigned study will offer more measurable outcomes that will yield better results that will play an integral role in further research down the line. So far, the contract has already been signed with an animal testing laboratory. Additionally, all the test articles have been manufactured and are being shipped to the lab for dosing purposes. Animal dosing is scheduled to start in July, and reporting will be provided as soon as there are significant developments in the study. About Lexaria Bioscience Corp Lexaria is a pioneer and global innovator in drug delivery platforms. Its patented technology, DehydraTECH(TM), has proven revolutionary in the delivery of fat-soluble active molecules and drugs. The technology functions by improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily through promoting healthier oral ingestion and increasing the efficacy of the fat-soluble active molecules. This company relies on applied R&D programs to generate confirmatory results and data evidencing improved drug delivery characteristics that allow for the achievement of commercial opportunities and/or corporate relationships. The 2021 applied R&D program is the embodiment of Lexaria’s commitment to this course. Its status update on the six studies within the R&D program indicates bigger things to come for the company from a research standpoint. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Dealmaker boasts over three years in the market, with a consistent track record of triple-digit year-over-year growth and 30+ deals launched on its platform every month
• The company is committed to delivering transformational innovation to the capital markets
• Its robust, market leading technology is adaptable to client needs and strategically designed for growth into new markets and deal types
• Dealmaker is ideally positioned to capitalize on the rapid growth and transformation of the capital markets, particularly in Reg A+, CF and 506c and 506b, as well as internationally
• The company is led by a seasoned management team supported by a network of experienced advisors

DealMaker is the leading technology solution for companies looking to raise capital faster and more efficiently. Companies of all sizes – from startups to blue chips – use DealMaker to launch and market their offerings to investors across the globe. DealMaker is the only complete solution for companies raising capital, providing a seamless investor experience and a complete deal CRM with real-time data and analytics, as well as investor management and engagement tools. Companies using DealMaker complete their raises up to 75% faster and over 80% cheaper than traditional methods of capital raising. Since its founding in 2017, nearly 1,000 capital raises have been completed on DealMaker, including some of the most successful raises in the past three years. DealMaker has offices in Toronto, Ontario, and Tampa, Florida. Solutions for Any Type of Capital Raise A Seamless Investor Journey Whether investors start their journey by clicking an ‘Invest Now’ link or by receiving a custom email invitation, DealMaker leverages a proprietary question flow that allows investors to complete their subscription agreement in minutes as opposed to hours. DealMaker digitizes and breaks down the subscription agreement into its core components to ensure investors are only answering the questions relevant to them. This helps to guarantee that investments are secured at the time of interest and with no deficiencies. Companies raising on DealMaker have significantly lower costs, as much as 90% less, due to the elimination of document review and back-and-forth. Digital Payments, AML and Accredited Investor Verification The investors’ journey doesn’t end when they sign the subscription agreement. DealMaker has the most robust suite of payment options, including credit card and secure bank-to-bank transfers, to allow investors to pay for their investments immediately and using the methods they prefer. Digital payments increase conversion rates and average investment amounts on every type of deal by removing friction in the payment process. DealMaker also has automated AML built into the platform – a feature that’s crucial for any marketed raise, including Reg A+ and Crowdfunding, but also anytime investments are accepted from unknown investors. For 506c raises, DealMaker also has Accredited Investor Verification built into the platform, eliminating painful back-and-forth to ensure investors are verified. In addition to ensuring that the investor has a seamless journey, Digital payments, AML and Accredited Investor Verification efficiently remove the pain of managing payments, background checks and verification from the company raising capital. A Complete CRM for the Raise Raising capital can be an arduous process, particularly when it comes to managing back-and-forth and investor follow-up to get the deal closed. DealMaker eliminates that pain by providing a full deal CRM to all companies raising on its platform. DealMaker offers real-time data on investor progress and payments, automated reminders to drive conversion, contact information and interaction data, as well as tagging and notes to manage investor interactions and follow-ups. DealMaker also offers full payment reconciliation to ensure all books and records are accurate and companies using its technology can close quickly. Companies using DealMaker are able to maximize conversion on their deals and close their raises up to 75% faster. Additional Benefits of DealMaker

• Analytics – DealMaker has the most powerful analytical suite on the market. Real-time data provides information at a glance on the performance of the raise, including funnel analytics, conversion, investor progress and payments. DealMaker provides customers with the data they need to ensure their raise is progressing well. For marketed raises, including Regulation A+, Crowdfunding, 506c and Offering Memorandums, DealMaker has a full suite of marketing attribution tools to track the success of the marketing spend.
• Shareholder Engagement and Management – The DMEngage shareholder management and engagement tool allows companies to share information, news releases and documents with current and potential investors and stakeholders before, during and after the raise. Investors and stakeholders also have access to all their information and documents in a branded portal. Whether it is a testing the waters campaign, uploading a DRS statement or sharing the companies’ latest quarterly results, DMEngage allows companies to manage all non-raise communication and engagement. DealMaker’s extensive research has shown that companies that engage their shareholders and stakeholders regularly raise more and faster and have more successful subsequent rounds.
• Partners and Expertise – Having completed nearly 1,000 raises, DealMaker has unparalleled experience in capital raising. DealMaker’s customer success team prepares a detailed plan for each raise to ensure no detail is missed and customers are set up for success. DealMaker has also established the largest network of partners in the space. Whether customers need a marketing partner, a financial publisher, a broker dealer, a law firm, an auditor or investor relations, DealMaker can make referrals and ensure they have the right team in place for a successful raise.

Types of Raises

• Regulation A+, 506c and Crowdfunding – Companies completing marketed raises on DealMaker own their brands and drive investors through a landing page that lives on the companies’ own website. Reg A+, 506c and Crowdfunding are the ultimate marketing tools, allowing companies to engage and grow their customer bases while raising capital. Marketed raises also have access to DealMaker’s best-in-class solutions, including digital payment tools, automated AML checks and Accredited Investor Verification services. As a result, companies raising via Reg A+, Reg CF and 506c on DealMaker have higher average investment amounts and conversion.
• Seed Rounds, 506b, Accredited Investors and Funds – DealMaker’s solutions for traditional capital raises and funds start with a digitized subscription agreement and proprietary question flow. No matter how complex the raise, DealMaker’s question flow ensures subscription agreements are completed in minutes, with no deficiencies.

Executive Team DealMaker Co-Founder and CEO Rebecca Kacaba has been honored as one of Lexpert’s ‘Top 40 Under 40’ in the legal field and was recognized as one of North America’s most innovative lawyers by the Financial Times. She practiced law on Bay Street for over 10 years and was co-chair of the Toronto Venture Technology and Emerging Growth Companies Group at a law firm while she worked as an M&A attorney in Canada’s financial district. The company’s Co-Founder and Chief Strategy Officer, Mat Goldstein has practiced law on Wall Street and Bay Street, also gaining recognition from Financial Times as one of North America’s most innovative lawyers. Prior to launching DealMaker, he built and advised several startup enterprises. DealMaker’s Chief Technology Officer is Geronimo de Abreu. With experience running his own development firm and scaling numerous companies through startup and growth, Mr. de Abreu has a diverse background in computer engineering, entrepreneurship and business strategy (MBA) to take DealMaker to the next level. DealMaker’s VP of Sales and Marketing, Michael Werry has over a decade of experience successfully building and leading sales organizations in both the SaaS and financial services industries, ranging from startups to SME’s with over $750 million in annual revenue. He brings a wealth of experience in scaling organizations through periods of exponential growth. The company’s VP Finance, Frank Jessop is a CFA, CPA, CA with a BMath in Stats from Waterloo. He provided leadership to the PwC emerging growth companies group before leading Sensibill through its Series B over the course of the last five years. The company is also supported by advisers with decades of experience in the capital markets and their foundational technologies. For more information, visit the company’s website at www.DealMaker.tech. NOTE TO INVESTORS: The latest news and updates relating to DealMaker are available in the company’s newsroom at https://ibn.fm/Deal

• XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule”
• The program, which started in early 2021, is slated for completion in late Q3 2021
• The first initial production batches were completed successfully, marking a significant milestone for the program
• Mescaline will form a critical component in XPhyto’s psychedelic medicine program and work towards providing a foundation for its drug formulation and clinical validation work

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) recently announced that its Good Manufacturing Practices (“GMP”) mescaline synthesis program in North America is “on schedule” for completion in late Q3 2021 (https://ibn.fm/ZRVGJ). So far, the company has completed the production of the initial batches and streamlined operations in readiness for scaling Its current focus is on the growth of production capability and the development of analytical methods of validation. “With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto’s psychedelic medicine program is progressing on schedule. As the manufacturing programs advance, we look forward to focusing our expertise on psychedelic drug formulation,” said Hugh Rogers, XPhyto’s CEO (https://ibn.fm/PDtV9). Back in early 2021, XPhyto announced its move to focus its resources and expertise on using active pharmaceutical ingredients for neurological application. These included psychedelic compounds, such as mescaline and psilocybin, and cannabinoids. The two psychedelic compounds form critical components in the company’s psychedelic medicine program, while working towards providing a foundation for its drug formulation and clinical validation work. This Vancouver-based life sciences technology accelerator is known for constantly pushing the envelope in bioscience research, focusing on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities. So far, it has made considerable strides in precision transdermal and oral dissolvable drug formulations, the rapid, low-cost infectious disease and oral health screening tests and, most importantly, the standardization of emerging active pharmaceutical ingredients for neurological applications (https://ibn.fm/Kuid3). XPhyto is confident that mescaline can become the next frontier in the current ongoing psychedelics renaissance. It is a product that presents the opportunity to innovate and improve on existing methods of mental health therapy, having already proven effective in the treatment of mental health-related medical conditions that include, but are not limited to anxiety, depression, addiction and trauma-related stress disorder. Mescaline is a naturally occurring psychedelic compound, typically found in specific cacti. In a recent publication by ACS Pharmacology and Translational Science, it was noted that the naturalistic use of mescaline is linked to psychiatric improvements and lasting positive life changes. It was further pointed out that its use among individuals with alcohol and drug use disorders (“AUD” and “DUD”), along with post-traumatic stress disorder (“PTSD”), all reported significant improvement following mescaline use and accompanying treatment (https://ibn.fm/lYWAo). With the current strides that XPhyto is making with its mescaline program, it is slowly laying the foundation for mental health therapy and the treatment of various mental health-related conditions. Additionally, it further plays a more significant role in sensitizing society on the usefulness and potential of psychedelic compounds and cannabinoids. XPhyto is also serving as proof of the financial viability of pharmaceutical-grade psychedelics and their use in treating psychological illnesses. “We see a significant market opportunity in the production of pharmaceutical-grade psychedelics followed by the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use,” Hugh mentioned. Currently, XPhyto has development operations in North America and Europe and an operational focus in Germany. As it focuses on scaling up its production capability, the company is also working on developing standard operating procedures (“SOP”) for GMP certification of its synthesis process. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF